Five-year outcomes of the China National Free Antiretroviral Treatment Program

Annals of Internal Medicine

Volumn 151, Issue 4, 2009, Pages 241-251

  Zhang, Fujie ^a   Dou, Zhihui ^a   Ma, Ye ^a   Zhao, Yan ^a   Liu, Zhongfu ^a   Bulterys, Marc ^b   Chen, Ray Y ^c  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Dongwai Diplomatic Office   (China)

^c US Embassy Beijing/NIH ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHINA; COHORT ANALYSIS; DATA BASE; FEMALE; FOLLOW UP; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION; DEVELOPING COUNTRY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; OUTCOME ASSESSMENT; SHORT SURVEY; VIRUS RESISTANCE; HEALTH CARE QUALITY; IMMUNOLOGY; MIDDLE AGED; PUBLIC HEALTH; STATISTICS; SURVIVAL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHINA; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PROGRAM EVALUATION; PROSPECTIVE STUDIES; STATISTICS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 68249143696     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-151-4-200908180-00006     Document Type: Article

References (49)

1. Wang L, Wang N, Wang L, Li D, Jia M, Gao X, et al. The 2007 estimates for people at risk for and living with HIV in China: progress and challenges. J Acquir Immune Defic Syndr. 2009;50:414-418 [PMID: 19214116]
2. State Council AIDS Working Committee Office, UN Theme Group on AIDS in China. A Joint Assessment of HIV/AIDS Prevention, Treatment and Care in China (2007). Beijing, China: Ministry of Health; 2007.
3. Zhang FJ, Pan J, Yu L, Wen Y, Zhao Y. Current progress of China's free ART program. Cell Res. 2005;15:877-882 [PMID: 16354563] (Pubitemid 41826254)
4. Zhang F, Haberer JE, Wang Y, Zhao Y, Ma Y, Zhao D, et al. The Chinese free antiretroviral treatment program: challenges and responses. AIDS. 2007;21 Suppl 8:S143-8. [PMID: 18172383]
5. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793 [PMID: 16905784] (Pubitemid 44223102)
6. Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353:2325-2334 [PMID: 16319381] (Pubitemid 41713744)
7. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342 [PMID: 16631912]
8. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al; Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006; 367:817-824 [PMID: 16530575]
9. Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41:217-224 [PMID: 15983918] (Pubitemid 40962502)
10. Jahn A, Floyd S, Crampin AC, Mwaungulu F, Mvula H, Munthali F, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet. 2008;371:1603-1611 [PMID: 18468544] (Pubitemid 351626844)
11. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18:887-895 [PMID: 15060436]
12. Corey DM, Kim HW, Salazar R, Illescas R, Villena J, Gutierrez L, et al. Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr. 2007;44:451-455 [PMID: 17195766] (Pubitemid 46555381)
13. Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, et al. Response to highly active antiretroviral therapy among severely immunocompromised HIV-infected patients in Cambodia. AIDS. 2007;21:351-359 [PMID: 17255742] (Pubitemid 46175047)
14. Laurent C, Ngom Gueye NF, Ndour CT, Gueye PM, Diouf M, Diakhaté N, et al; ANRS 1215/1290 Study Group. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005;38:14-17 [PMID: 15608518]
15. Fairall LR, Bachmann MO, Louwagie GM, van Vuuren C, Chikobvu P, Steyn D, et al. Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med. 2008;168:86-93. [PMID: 18195200]
16. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, Pinoges L, et al. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS. 2007;21:2293-2301 [PMID: 18090277] (Pubitemid 350287455)
17. Grinsztejn B, Veloso VG, Pilotto JH, Campos DP, Keruly JC, Moore RD. Comparison of clinical response to initial highly active antiretroviral therapy in the patients in clinical care in the United States and Brazil. J Acquir Immune Defic Syndr. 2007;45:515-520 [PMID: 17558332] (Pubitemid 47294923)
18. Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behumbiize P, et al. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet. 2008;371:752-759 [PMID: 18313504] (Pubitemid 351297773)
19. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al; Aconda Study Group. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22:873-882 [PMID: 18427206]
20. Sherer R, Gui X, Zhan F, Teter C, Ping DL, Wykoff RF. Rapid antiretroviral therapy scale-up in Hubei Province, China. Health Aff (Millwood). 2008; 27:1140-1147 [PMID: 18607048]
21. Van der Borght SF, Clevenbergh P, Rijckborst H, Nsalou P, Onyia N, Lange JM, et al. Mortality and morbidity among HIV type-1-infected patients during the first 5 years of a multicountry HIV workplace programme in Africa. Antivir Ther. 2009;14:63-74. [PMID: 19320238]
22. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, Puvimanasinghe J, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS. 2008;22:2303-2311 [PMID: 18981769]
23. Zhang FJ, ed. China Free ART Manual. Beijing, China: Chinese Center for Disease Control and Prevention; January 2005.
24. Ma Y, Zhang F, Zhao Y, Zang C, Zhao D, Dou Z, et al. Cohort profile: the Chinese national free antiretroviral treatment cohort. Int J Epidemiol. 25 June 2009. [Epub ahead of print] [PMID: 19556327]
25. Chinese Center for Disease Control and Prevention. China Free ART Manual. Beijing, China: Ministry of Health; 2005.
26. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendation for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2006.
27. Marazzi MC, Liotta G, Germano P, Guidotti G, Altan AD, Ceffa S, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses. 2008;24:555-560 [PMID: 18366314] (Pubitemid 351571039)
28. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, et al; Academic Alliance for AIDS Care and Prevention in Africa. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;46:187-193 [PMID: 17693883]
29. Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, Aglen HE, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis. 2008;8:52. [PMID: 18430196] (Pubitemid 351619259)
30. Barth RE, van der Meer JT, Hoepelman AI, Schrooders PA, van de Vijver DA, Geelen SP, et al. Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. Eur J Clin Microbiol Infect Dis. 2008;27:977-984 [PMID: 18629557]
31. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa [Editorial]. AIDS. 2008;22:1897-1908 [PMID: 18784453]
32. Zhang F, Dou Z, Yu L, Xu J, Jiao JH, Wang N, et al. The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis. 2008;47:825-833 [PMID: 18690805]
33. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577 [PMID: 11722271] (Pubitemid 33096808)
34. Antiretroviral Therapy Cohort Collaboration. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007;46:607-615 [PMID: 18043315]
35. Zhou J, Paton NI, Ditangco R, Chen YM, Kamarulzaman A, Kumarasamy N, et al. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database. HIV Med. 2007;8:8-16. [PMID: 17305926] (Pubitemid 46117835)
36. Hosseinipour M, van Oosterhout J, Weigel R, Mzigangira D, Saukila N, Mhango B, et al. Validating clinical and immunological definitions of antiretroviral treatment failure in Malawi [Abstract WEAB101]. Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia.
37. Basenero A, Castelnuovo B, Birabwa E, John L, MacAdam K, Schlech W, et al. Inadequacy of clinical and immunological criteria in identifying virologic failure of 1st line ART: the Ugandan experience [Abstract WEAB102]. Fourth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia.
38. Moore DM, Mermin J, Awor A, Yip B, Hogg RS, Montaner JS. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr. 2006;43:436-439 [PMID: 17019367] (Pubitemid 44737101)
39. Bisson GP, Gross R, Strom JB, Rollins C, Bellamy S, Weinstein R, et al. Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy. AIDS. 2006;20:1613-1619 [PMID: 16868442] (Pubitemid 44162403)
40. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS. 2008;22:1971-1977 [PMID: 18784460]
41. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, Mogorosi M, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS ONE. 2008;3:e1725. [PMID: 18320045] (Pubitemid 351903231)
42. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med. 2008;5:e109. [PMID: 18494555]
43. Lima VD, Harrigan R, Bangsberg DR, Hogg RS, Gross R, Yip B, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50:529-536 [PMID: 19223785]
44. Reynolds SJ, Nakigozi G, Newell K, Ndyanabo A, Galiwongo R, Boaz I, et al. Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS. 2009;23:697-700. [PMID: 19209067]
45. Moore DM, Mermin J. Monitoring antiretroviral failure in resource-poor settings. Lancet. 2008;371:1396-1397 [PMID: 18440414] (Pubitemid 351611658)
46. Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet. 2008;371:1443-1451 [PMID: 18440426] (Pubitemid 351635534)
47. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, Singh S, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006;296:679-690 [PMID: 16896111] (Pubitemid 44200639)
48. Keiser O, Anastos K, Schechter M, Balestre E, Myer L, Boulle A, et al; ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA). Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health. 2008;13:870-879 [PMID: 18373510]
49. Bartlett JG. Significant challenges facing HIV practitioners. J Infect Dis. 2008;197 Suppl 3:S250-1. [PMID: 18447610]